Public Company Healthcare

Inotiv

West Lafayette, Indiana, United States

Contract research organization (CRO) providing nonclinical and analytical drug discovery and development services, including research models and related services and products.

Focus Areas
Contract Research Organization (CRO), Nonclinical / preclinical research, Analytical drug discovery and development
Website
inotiv.com

Tracked deals

3

3 tracked deals across 2021-2022.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Inotiv Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Inotiv. 1 2021 2 2022

Supporting Data

Recent Transactions

  • Inotiv Acquires Protypia to Expand Protein/Peptide Bioanalytical Capabilities
    July 7, 2022
    Buyer
    Inotiv, Inc.
    Target
    Protypia, Inc.
    Industry
    Healthcare Services
    Location
    Tennessee, United States
    Type
    Buyout

    Inotiv, Inc. completed the acquisition of Nashville-based Protypia, Inc., a protein/peptide bioanalytical company, for approximately $11.0 million in a combination of cash, Inotiv common shares and promissory notes. The deal adds quantitative tissue-based large-molecule mass spectrometry capabilities to Inotiv's bioanalytical offerings to support immuno-oncology, cell and gene therapy, and other drug development programs.

  • Inotiv Acquires Integrated Laboratory Systems (ILS)
    January 10, 2022
    Buyer
    Inotiv, Inc.
    Target
    Integrated Laboratory Systems, LLC
    Seller
    Sier Capital
    Industry
    Healthcare Services
    Location
    North Carolina, United States
    Type
    Buyout

    Inotiv, Inc. (NASDAQ: NOTV) completed the acquisition of Integrated Laboratory Systems, LLC (ILS), a contract research organization based in Morrisville, North Carolina, from Sier Capital. The transaction consideration totaled $56.0 million (approximately $38.0 million cash and 429,118 Inotiv shares valued at $18.0 million); ILS reported roughly $20.0 million of revenue in 2021 and will be integrated to expand Inotiv's genetic toxicology, in vivo/in vitro toxicology, pathology, genomics, and computational toxicology capabilities.

  • Inotiv Acquires HistoTox Labs
    April 13, 2021
    Buyer
    Inotiv, Inc.
    Target
    HistoTox Labs, Inc.
    Industry
    Healthcare Services
    Location
    Colorado, United States
    Type
    Buyout

    Inotiv, Inc. has entered into an agreement to purchase substantially all assets of HistoTox Labs, a histopathology contract research organization, for $22.0 million in cash. The acquisition (subject to financing and customary closing conditions) expands Inotiv's pathology and histology capabilities, adds a Boulder, Colorado facility with digital pathology and immunohistochemistry capabilities, and is expected to retain all HistoTox employees.

Related Acquisition Pages

Healthcare Services Buyers & Acquisitions 3 tracked deals by Inotiv. Acquisitions in Colorado 1 tracked deal by Inotiv. Acquisitions in North Carolina 1 tracked deal by Inotiv. Acquisitions in Tennessee 1 tracked deal by Inotiv.

Related articles

Selling a company? Get in front of buyers like Inotiv

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →